Takeda’s Norovirus Vaccine Misses Primary Endpoint in PI/II, but Reduces Vomiting, Diarrhea

Takeda Pharmaceutical said on October 7 that its investigational norovirus vaccine significantly lowered the incidence of vomiting and diarrhea compared to placebo in a PI/II clinical trial in the US, though the primary endpoint was not met. The randomized, double-blind,...read more